A Study To Assess The Pharmacokinetics, Safety, And Tolerability Of A Pregabalin Controlled Release Formulation Administered Following Various Sized Caloric Meals As Compared To The Pregabalin Immediate Release Formulation

NCT ID: NCT01080612

Last Updated: 2021-01-29

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2010-04-30

Study Completion Date

2010-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to (1) evaluate the effect of caloric intake on the pharmacokinetics of a single dose of a 330 mg pregabalin controlled release tablet relative to a 300 mg pregabalin immediate release capsule administered fasted and (2) determine the safety and tolerability of a single dose of a 330 mg pregabalin controlled release formulation administered following various sized caloric meals and the 300 mg pregabalin immediate release capsule administered fasted.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To assess the single dose pharmacokinetics, safety, and tolerability of pregabalin controlled release formulation following various sized caloric meals relative to the immediate release formulation.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

330 mg pregabalin controlled release: 400 to 500 calories

Group Type EXPERIMENTAL

330 mg pregabalin controlled release

Intervention Type DRUG

A single dose of 330 mg controlled release tablet will be administered following a 400 to 500 calorie meal

330 mg pregabalin controlled release: 600 to 750 calories

Group Type EXPERIMENTAL

330 mg pregabalin controlled release

Intervention Type DRUG

A single dose of 330 mg controlled release tablet will be administered following a 600 to 750 calorie meal

330 mg pregabalin controlled release: 800 to 1000 calories

Group Type EXPERIMENTAL

330 mg pregabalin controlled release

Intervention Type DRUG

A single dose of 330 mg controlled release tablet will be administered following an 800 to 1000 calorie meal

300 mg pregabalin immediate release

Group Type OTHER

300 mg pregabalin immediate release

Intervention Type DRUG

A single dose of 300 mg immediate release capsule will be administered in the fasted state

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

330 mg pregabalin controlled release

A single dose of 330 mg controlled release tablet will be administered following a 400 to 500 calorie meal

Intervention Type DRUG

330 mg pregabalin controlled release

A single dose of 330 mg controlled release tablet will be administered following a 600 to 750 calorie meal

Intervention Type DRUG

330 mg pregabalin controlled release

A single dose of 330 mg controlled release tablet will be administered following an 800 to 1000 calorie meal

Intervention Type DRUG

300 mg pregabalin immediate release

A single dose of 300 mg immediate release capsule will be administered in the fasted state

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male or females
* Between the ages of 18 and 55 years, inclusive
* Body Mass Index (BMI) of 17.5 to 30.5 kg/m2

Exclusion Criteria

* Illicit drug use
* Pregnant or nursing females
* Females of childbearing potential who are unwilling or unable to use an acceptable method of contraception
Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pfizer CT.gov Call Center

Role: STUDY_DIRECTOR

Pfizer

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Pfizer Investigational Site

New Haven, Connecticut, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Chew ML, Plotka A, Alvey CW, Pitman VW, Alebic-Kolbah T, Scavone JM, Bockbrader HN. Pharmacokinetics of pregabalin controlled-release in healthy volunteers: effect of food in five single-dose, randomized, clinical pharmacology studies. Clin Drug Investig. 2014 Sep;34(9):617-26. doi: 10.1007/s40261-014-0211-4.

Reference Type DERIVED
PMID: 25078976 (View on PubMed)

Related Links

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

A0081239

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.